Role of Mesenchymal Stromal Cell Derived Extracellular Vesicles of Primary Myelofibrosis Patients on CD34+ Cells

Launched by FONDAZIONE IRCCS POLICLINICO SAN MATTEO DI PAVIA · Mar 19, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating how certain cells in the bone marrow, called mesenchymal stromal cells (MSCs), send signals that might affect the development of blood cells in patients with primary myelofibrosis (PMF). PMF is a condition where the bone marrow doesn’t function properly, leading to abnormal blood cell production. Researchers want to understand how MSCs from PMF patients differ from those in healthy individuals and how these differences may impact the maturation of specific blood cells, known as CD34+ cells, which are important for producing healthy blood. By studying small vesicles released by MSCs, the team hopes to gain insights that could eventually lead to new treatments.

To participate in this trial, individuals must be at least 18 years old and diagnosed with PMF, specifically having a mutation called JAK2 V617F. Participants should not be receiving any treatment for their PMF and should not have had a spleen removal or a previous bone marrow transplant. During the study, participants can expect to provide bone marrow samples, which will be used to study the MSCs and their effects on blood cell development. This trial aims to find new ways to help improve the health of patients with PMF and may lead to the development of innovative therapies in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with PMF
• • JAK2 V617F+ (either homozygous or heterozygous)
• • Out of therapy
• • At least 18 years old
• Exclusion Criteria:
• • PMF combined to other pathologies
• • Previous splenectomy
• • Previous bone marrow transplant